SAGE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.69 USD | +0.81% |
|
+2.70% | -36.83% |
| 04-25 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
| 04-25 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
| Sales 2024 * | 38.31M 3.07B | Sales 2025 * | 138M 11.06B | Capitalization | 824M 65.95B |
|---|---|---|---|---|---|
| Net income 2024 * | -399M -31.94B | Net income 2025 * | -325M -26.02B | EV / Sales 2024 * | 7.68 x |
| Net cash position 2024 * | 530M 42.39B | Net cash position 2025 * | 337M 26.95B | EV / Sales 2025 * | 3.53 x |
| P/E ratio 2024 * |
-2.06
x | P/E ratio 2025 * |
-2.72
x | Employees | 487 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.4% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sage Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | +0.81% | ||
| 1 week | +2.70% | ||
| Current month | -26.95% | ||
| 1 month | -26.48% | ||
| 3 months | -48.07% | ||
| 6 months | -26.36% | ||
| Current year | -36.83% |
1 week
12.74
14.97
1 month
10.9219.34
Current year
10.9228.26
1 year
10.9259.99
3 years
10.9280.87
5 years
10.92193.56
10 years
10.92195.97
| Managers | Title | Age | Since |
|---|---|---|---|
Barry Greene
CEO | Chief Executive Officer | 60 | 30/09/20 |
Steven Paul
FOU | Founder | 73 | 15/04/10 |
Kimi Iguchi
DFI | Director of Finance/CFO | 61 | 28/02/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jeff Jonas
BRD | Director/Board Member | 71 | 13/08/13 |
Steven Paul
FOU | Founder | 73 | 15/04/10 |
Barry Greene
CEO | Chief Executive Officer | 60 | 30/09/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.13% | 16 M€ | -8.49% | ||
| 0.21% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 13.69 | +0.81% | 1,493,679 |
| 25/04/24 | 13.58 | -3.00% | 1,414,569 |
| 24/04/24 | 14 | +8.11% | 2,521,967 |
| 23/04/24 | 12.95 | +0.47% | 815,185 |
| 22/04/24 | 12.89 | -3.30% | 803,340 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
13.69
USD
Average target price
22.67
USD
Spread / Average Target
+65.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -36.83% | 824M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SAGE Stock
